Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 6.38%.

  • GeneDx Holdings' EBITDA Margin rose 38400.0% to 6.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54%, marking a year-over-year increase of 314400.0%. This contributed to the annual value of 16.99% for FY2024, which is 695800.0% up from last year.
  • As of Q3 2025, GeneDx Holdings' EBITDA Margin stood at 6.38%, which was up 38400.0% from 10.44% recorded in Q2 2025.
  • GeneDx Holdings' EBITDA Margin's 5-year high stood at 75.8% during Q3 2021, with a 5-year trough of 503.28% in Q4 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 69.52% (2021), whereas its average is 95.22%.
  • As far as peak fluctuations go, GeneDx Holdings' EBITDA Margin tumbled by -4337500bps in 2022, and later soared by 4591300bps in 2023.
  • Over the past 5 years, GeneDx Holdings' EBITDA Margin (Quarter) stood at 69.52% in 2021, then plummeted by -624bps to 503.28% in 2022, then surged by 91bps to 44.15% in 2023, then surged by 113bps to 5.59% in 2024, then crashed by -214bps to 6.38% in 2025.
  • Its last three reported values are 6.38% in Q3 2025, 10.44% for Q2 2025, and 7.41% during Q1 2025.